AI agents, software that can plan, call tools, and take multi-step action toward a goal, are arriving in life sciences faster than most quality organizations expected. Late in 2025, major platform vendors began embedding generative AI agents directly into validated systems used for CRM, promotional content, safety, and clinical operations. The question for regulated companies is no longer whether to allow agents, but how to govern them without either rubber-stamping risk or freezing innovation in committee.
The good news is that the regulatory ground has shifted to meet the moment. A cluster of 2025-2026 developments: the FDA's Computer Software Assurance (CSA) guidance emphasizing risk-based, intended-use validation over exhaustive scripted testing; a draft revision of the EU's Annex 11 that explicitly addresses cloud and SaaS and mandates immutable audit logs; and emerging FDA/EMA principles for good AI practice in drug development, collectively point toward a coherent way to govern AI in a GxP context. The frameworks exist. The work is applying them.
Start With Intended Use and Risk
The single most important governance decision is scoping: what is this agent actually allowed to do, and what happens if it is wrong? Risk-based assurance means you calibrate rigor to consequence.
- Low-risk, reversible, internal tasks, summarizing a document for an analyst, drafting a first-pass query, warrant lighter validation and monitoring.
- High-risk, GxP-impacting tasks, anything that touches a regulated record, a safety signal, a submission, or patient-facing content, demand full validation, formal review, and constrained autonomy.
Write the intended use down. An agent's permissions, tools, and data access should flow from a documented statement of what it is for, not from whatever the underlying model happens to be capable of.
Human-in-the-Loop Is the Defensible Default
For any AI-influenced record that requires an electronic signature under 21 CFR Part 11, the most defensible pattern is human-in-the-loop: a qualified individual meaningfully reviews the AI's output before signing. "Meaningfully" is the operative word: a review that is a reflexive click is not a control. Governance should ensure the reviewer has the context, the citations, and the time to actually evaluate what they are approving.
This reframes the agent's role. It is a highly capable assistant that prepares work for a qualified human, not an autonomous actor that commits regulated records on its own. That framing keeps accountability where regulators expect it: with people.
The Controls That Make Agents Auditable
An agent that cannot be inspected cannot be validated. Several controls turn a black box into a governable system:
- Immutable audit trails. Capture the prompt, the retrieved data, the tools invoked, the intermediate steps, the output, and the human decision. The revised Annex 11 direction toward tamper-evident logging is exactly this.
- Access and data-scope controls. An agent inherits the access rights it is granted, no more. PHI and other sensitive data stay behind existing controls; the agent does not become a side channel around them.
- Constrained tool use. Whitelist the actions an agent can take. An agent that can read a system is very different from one that can write to it; production write access is a deliberate, high-scrutiny grant.
- Change management. The model, prompts, and retrieval sources are all part of the validated state. When any of them changes, revalidation is triggered, because a model update can silently change behavior.
Continuous Validation, Not a One-Time Event
Traditional validation assumed static software: validate once, lock it down. Agentic and SaaS-delivered systems are dynamic, models are updated, vendors push changes, behavior drifts. The regulatory direction toward continuous validation reflects this. Practically:
- Maintain evaluation suites that re-test agent behavior on representative, high-risk scenarios on a schedule and on every material change.
- Monitor production behavior for drift and unexpected actions, with sampling and automated scoring.
- Treat vendor model updates as change-control events, with a defined assessment before they reach validated workflows.
This is where quality, IT, and data science have to operate as one team rather than as sequential gatekeepers. The governance model that works pairs technical guardrails (AI enablement and LLMOps) with quality-system discipline.
The Takeaway
Governing AI agents in a GxP environment is not about writing a policy that says "no." It is about a risk-based framework that says a clear "yes, within these bounds": intended use documented, autonomy constrained to match consequence, human-in-the-loop on anything that signs a regulated record, immutable audit trails on everything, and continuous validation because the system will not hold still. The 2025-2026 guidance gives regulated companies the vocabulary and the permission to move. The organizations that build this framework now, rather than reacting after a deployment goes sideways, will be the ones that get the productivity of agents without trading away compliance.